Los Angeles, CA – 03-27-2020 (PRDistribution.com) — (Los Angeles, CA) – DxTerity Diagnostics announced today that it is developing a business enterprise solution to assist in making the workplace safer in a COVID-19 world. The “KEEP AMERICA WORKING” subscription service is targeted at employers looking for a way to reduce the risk of COVID-19 spread while still allowing business to operate. The service is designed to fulfill a tremendous unmet need as workers return to their places of employment in the coming months.
The service is powered by DxTerity’s DxDirect® high-throughput genomics platform and is designed to provide next-day, de-identified, company-wide COVID-19 testing results. Service subscribers will receive a weekly or bi-weekly shipment of uniquely barcoded nasal swabs for employee testing. Employees will self-collect nasal samples, and the de-identified sample IDs will be entered by a site coordinator into a private company portal. The collection devices will then be shipped to DxTerity for testing, with results delivered electronically the next day.
DxTerity is also expanding its product portfolio of DxCollect® sample collection devices to include a nasal swab that inactivates the COVID-19 virus and enables safe, non-infectious transport of COVID-19 samples.
“The COVID-19 pandemic has motivated many companies across the US to explore how they can help save lives and keep America working,” says Bob Terbrueggen, Ph.D., Founder and CEO of DxTerity. “DxTerity has spent a considerable amount of time developing high-throughput testing solutions for both Government (BARDA) emergency response situations and for leading biopharma and healthcare providers, including ‘from-home’ genomic monitoring of autoimmune patients. Our patented DxDirect® and DxCollect® technologies bring unique scalability and sample access to the COVID-19 problem. This surveillance solution can quickly scale to hundreds of thousands of workers being screened each week.”
About DxTerity: DxTerity is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring.
DxDirect® and DxCollect® are registered trademarks of DxTerity Diagnostics, Inc.
For the original news story, please visit https://prdistribution.com/news/dxterity-announces-upcoming-launch-of-covid-19-employee-screening-service.html.
Powered by WPeMatico